Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Aram F. Hezel, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-9484

Office: (585) 275-5823

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

I chose this field because as a young man, I was profoundly impacted by the death of my grandfather from cancer, and then later in medical school, I was drawn at a scientific and personal level to the care of people facing cancer.
?Every patient is different – and so is each cancer. Doing the best I can to understand patients and their families, what is important to them and providing the best possible care is my goal. While many people face cancer, each person does so with specific concerns, fears and beliefs. I will always do my best to provide the highest quality care, while preserving a patient's dignity.

My areas of special interest include clinical trials with new therapies for gastrointestinal cancers, and understanding the genetics and biology of pancreatic and liver cancers.

Conditions I Treat

- Esophageal cancer
- Stomach cancer
- Liver cancer
- Pancreatic cancer
- Bowel cancer
- Colon cancer
- Rectal cancer
- Anal cancer
- Gastrointestinal stromal tumors (GIST)
- Neuroendocrine tumors
- Carcinoid tumors

Credentials

Specialties

  • Internal Medicine
  • Medical Oncology

Education

2000
MD | SUNY Buffalo School of Medicine

Post-doctoral Training & Residency

07/01/2003 - 06/30/2006
Fellowship in Medical Oncology at Dana Farber Cancer Institute/ Partners

07/01/2001 - 06/30/2003
Residency in Internal Medicine at Beth Israel Deaconess Medical Center

07/01/2000 - 06/30/2001
Internship in at Beth Israel Deaconess Medical Center

VIEW ALL expand_more

Awards

2013
Patient & Family Centered Care Top Performer Award
Location: University of Rochester, American Cancer Society

2013
American Cancer Society Career Development Award

2012
Teacher of the Year Award
Location: University of Rochester, Division of Hematology & Oncology

2011
Teacher of the Year Award
Location: University of Rochester, Division of Hematology & Oncology

2010
Edelman Gardner Research Award
Location: University of Rochester, Wilmot Cancer Center

2007
Howard Hughes Medical Institute Physician-Scientist Early Career Award

2006
NCI Career Development Award: K08 CA122835-03

2005
PanCAN/ASCO Young Investigator Award

2000
Loretta A. Jordan Award for Research of Neoplastic Disease

2000
Robin Bannerman Memorial Research Award

1999
Howard Hughes Medical Institute Research Training Fellowship for Medical Students

1998
Howard Hughes Medical Institute Research Training Fellowship

1997
John Harford/American Federation for Aging Research
Location: Medical School Research Fellowship

1996 - 1997
Dean's List for Academic Excellence
Location: SUNY Buffalo School of Medicine

VIEW ALL expand_more

Clinical Trials

Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery (A021602)

Lead Researcher: Aram F Hezel

This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery after previous treatment with everolimus. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

View Study Details

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers (S1815),

Lead Researcher: Aram F Hezel

This phase III trial studies how well gemcitabine hydrochloride and cisplatin - given with or without nab-paclitaxel - work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not known if giving gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel may work better at treating biliary tract cancers.

View Study Details

Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma,Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Lead Researcher: Aram F Hezel

This is an open-label phase 1A/1B study to assess the safety, tolerability, and movement throughout the body (pharmacokinetics) of SBP-101 when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer (metastatic pancreatic ductal adenocarcinoma) and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.

View Study Details

CGIC-13038~N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Lead Researcher: Aram F Hezel

The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs, 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. This results in high rates of disease control with significant side effects. The purpose of this study is to compare the effects of the standard treatment of chemotherapy and radiation to chemotherapy alone. The aim of this study is to determine if we can reduce the side effects while still controlling the disease. The chemotherapy alone is the combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin). Depending on the response to FOLFOX you may also receive the standard treatment 5FUCMT. The drugs used in this study are all FDA (Food and Drug Administration) approved for the treatment of colorectal cancer. The use of FOLFOX chemotherapy alone in place of 5FUCMT is experimental. In case FOLFOX chemotherapy alone does not work, you will receive standard treatment which is 5FUCMT followed by surgery.

View Study Details

Publications

Journal Articles

9/4/2014
Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N. "Mutant IDH inhibits HNF-4? to block hepatocyte differentiation and promote biliary cancer." Nature.. 2014 Sep 4; 513(7516):110-4. Epub 2014 Jul 02.

7/29/2014
Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX. "Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer." British journal of cancer.. 2014 Jul 29; 111(3):430-6. Epub 2014 Jun 24.

5/22/2014
Kinsey C, Balakrishnan V, O'Dell MR, Huang JL, Newman L, Whitney-Miller CL, Hezel AF, Land H. "Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression." Cell reports.. 2014 May 22; 7(4):1143-55. Epub 2014 May 01.

Books & Chapters

2007
Chapter Title: "Stromal biology of pancreatic cancer."
Book Title: Journal of cellular biochemistry
Author List: Chu GC; Kimmelman AC; Hezel AF; DePinho RA
Published By: Journal of Cellular Biochemistry 2007

VIEW ALL PUBLICATIONS